Sandip P. Patel, MD, discusses the exploration of sacituzumab govitecan in the EVOKE-01 and EVOKE-02 trials in NSCLC and expands on future treatment directions with the agent in this patient population.
Bupathi highlights key points that were presented at an OncLive Institutional Perspectives in Cancer, including implications of the EV-302 trial findings; data updates from the phase 1/2 ICRA trial; and future directions for urothelial cancer.
Experts discuss the potential of triple combination therapies for high-risk renal cell carcinoma (RCC) patients and the challenges posed by their toxicity profiles, emphasizing the need for compelling clinical trial data.
Kai-Keen Shiu, MD, discusses the significance of the FDA approval of pembrolizumab in combination with fluoropyrimidine- and platinum-containing chemotherapy as a first-line treatment in patients with locally advanced, unresectable or metastatic, HER2-negative gastric or gastroesophageal junction adenocarcinoma.
In the phase 3 EV-302/KEYNOTE-A39 clinical trial, the antibody-drug conjugate enfortumab vedotin plus PD-1 inhibitor pembrolizumab nearly doubled both median overall survival and progression-free survival compared with chemotherapy.